← Back to Search

Internet-Based Communication and Education for Cancer

N/A

Waitlist Available

Led By Matthew Loscalzo

Research Sponsored by City of Hope Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

PHASE II AIM 2: Malignant diagnosis of breast, lung, or colorectal cancer at any stage

PHASE I AIM 3.1: Malignant diagnosis in any cancer type at any stage

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 months

Awards & highlights

Study Summary

This trial is testing a software program that lets patients communicate with their doctors and learn about their cancer and treatment options. The goal is to see if the program can help patients identify and get help to treat their symptoms.

Who is the study for?

This trial is for cancer patients with a life expectancy of at least six months, undergoing any type of cancer treatment, and have internet access. It's open to those with breast, gynecologic, genitourinary or colorectal cancers among others. Participants must be fluent in English and outpatient status is required. Pregnant women, prisoners, individuals with cognitive impairments or involved in other psychosocial studies are excluded.Check my eligibility

What is being tested?

The trial tests PatientCareAnywhere software designed to improve communication between cancer patients and healthcare providers and provide education about their condition and treatments. The study will see if this tool helps patients understand their symptoms better and communicate these effectively to their doctors.See study design

What are the potential side effects?

Since the intervention involves software use for communication and education without direct medical treatments or drugs being administered, there are no typical medication side effects; however, participants may experience issues related to technology use such as eye strain or stress from information overload.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with breast, lung, or colorectal cancer.

Select...

I have been diagnosed with cancer at any stage.

Select...

I am currently undergoing some form of cancer treatment.

Select...

I have been diagnosed with cancer in the breast, gynecologic, or genitourinary area.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Functional Assessment of Cancer Therapy-General (FACT-G) scores

Secondary outcome measures

Change in health resource utilization

Change in self-efficacy as measured by the revised Chronic Disease Self-Efficacy Scale

Other outcome measures

Individual patient changes in Functional Assessment of Cancer Therapy-General (FACT-G) total scores

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (PatientCareAnywhere program system)Experimental Treatment5 Interventions

Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.

Group II: Arm II (usual care)Active Control2 Interventions

Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor

565 Previous Clinical Trials

1,920,876 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,057 Total Patients Enrolled

Matthew LoscalzoPrincipal InvestigatorCity of Hope Medical Center

Media Library

Communication Intervention Clinical Trial Eligibility Overview. Trial Name: NCT02408406 — N/A

Colorectal Cancer Research Study Groups: Arm II (usual care), Arm I (PatientCareAnywhere program system)

Colorectal Cancer Clinical Trial 2023: Communication Intervention Highlights & Side Effects. Trial Name: NCT02408406 — N/A

Communication Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT02408406 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this experiment open to participants?

"Clinicaltrials.gov informs us that this experiment, which was first posted on July 7th 2015 and last modified on February 17th 2022, is no longer looking for participants. However, there are still 7762 other medical studies recruiting patients at the present time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers

2015. "PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02408406.

All > Genital Warts